Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Autologous stem cell transplantation (ASCT) is a key treatment for light chain (AL) amyloidosis.
• Limited data exists on the safety, efficacy, and patient selection for a second ASCT (ASCT2).
• Understanding ASCT2 utility is crucial for optimizing AL amyloidosis treatment strategies.

Purpose of the Study:

• To evaluate the feasibility and outcomes of ASCT2 in patients with relapsed or refractory AL amyloidosis.
• To identify patient subgroups who benefit most from ASCT2.
• To inform clinical decision-making regarding repeat ASCT in AL amyloidosis.

Main Methods:

• Retrospective analysis of AL amyloidosis patients undergoing ASCT2 between 2003 and 2020.
• Data collection included patient characteristics, prior therapies, ASCT procedures, and outcomes.
• Survival analyses were performed to identify factors associated with improved outcomes post-ASCT2.

Main Results:

• ASCT2 utilization increased from 2.5% to 5% of all ASCTs between 2003-2011 and 2012-2020.
• Progression-free and overall survival were significantly longer for patients with durable remission (≥5 years) after ASCT1 and those without intervening therapy.
• ASCT2 is feasible, with manageable engraftment issues and a 15% early mortality rate.

Conclusions:

• ASCT2 is a viable treatment option for select AL amyloidosis patients.
• Patients achieving durable remission after ASCT1 are more likely to benefit from ASCT2.
• ASCT2 should be considered at first progression in patients with a sustained response to initial ASCT.